细胞因子释放综合征
Cytokine release syndrome
近十年肿瘤免疫治疗进展迅速，免疫检查点抑制、双特异性T细胞衔接抗体和CAR-T细胞等疗法在临床试验中疗效显著，部分已获批上市。但这些强效疗法也带来可能致命的副作用，其中最突出的是细胞因子释放综合征。这篇综述全面梳理了该综合征的病理机制、危险因素、临床表现、鉴别诊断和预后因素，并基于现有证据给出实际管理建议。文章属于对已知问题的经验总结，不报告新的研究数据。
为什么推荐给您：针对已知不良反应的综述与临床管理建议，无原创数据或新机制。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T cells have shown remarkable efficacy in clinical trials and some of these agents have already received regulatory approval. However, along with growing experience in the clinical application of these potent immunotherapeutic agents comes the increasing awareness of their inherent and potentially fatal adverse effects, most notably the cytokine release syndrome (CRS). This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors. In addition, based on the current evidence we give practical guidance to the management of the cytokine release syndrome.